Sage Historical Income Statement
| SAGE Stock | USD 5.54 0.19 3.32% |
Historical analysis of Sage Therapeutic income statement accounts such as Research Development of 215.9 M, Total Operating Expenses of 363.2 M, Total Other Income Expense Net of 40.3 M or Total Revenue of 144.3 M can show how well Sage Therapeutic performed in making a profits. Evaluating Sage Therapeutic income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Sage Therapeutic's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Sage Therapeutic latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sage Therapeutic is a good buy for the upcoming year.
Sage |
About Sage Income Statement Analysis
Sage Therapeutic Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Sage Therapeutic shareholders. The income statement also shows Sage investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Sage Therapeutic Income Statement Chart
Add Fundamental
Most accounts from Sage Therapeutic's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Sage Therapeutic current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.At present, Sage Therapeutic's Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 144.3 M, whereas Selling General Administrative is forecasted to decline to about 144.2 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 2.9M | 14.2M | 36.1M | 37.9M | Net Interest Income | 2.9M | 14.2M | 36.1M | 37.9M |
Sage Therapeutic income statement Correlations
Click cells to compare fundamentals
Sage Therapeutic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sage Therapeutic income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 2.3M | 2.6M | 4.2M | 1.1M | 1.4M | 1.3M | |
| Selling General Administrative | 345.8M | 197.0M | 183.5M | 227.7M | 274.5M | 144.2M | |
| Other Operating Expenses | 715.0M | 490.2M | 467.2M | 554.7M | 666.3M | 363.6M | |
| Operating Income | (708.1M) | 596.2M | (460.9M) | (547.0M) | (579.8M) | (550.9M) | |
| Ebit | (708.1M) | 624.0M | (460.9M) | (547.0M) | (546.5M) | (519.1M) | |
| Research Development | 368.8M | 292.7M | 283.2M | 326.2M | 356.2M | 215.9M | |
| Ebitda | (705.8M) | 626.6M | (456.7M) | (545.9M) | (545.1M) | (517.8M) | |
| Total Operating Expenses | 714.6M | 489.7M | 466.7M | 553.9M | 664.1M | 363.2M | |
| Income Before Tax | (680.2M) | 606.1M | (457.9M) | (532.8M) | (541.5M) | (514.4M) | |
| Total Other Income Expense Net | 27.9M | 9.8M | 3.0M | 14.2M | 38.4M | 40.3M | |
| Net Income | (650.2M) | 606.1M | (450.8M) | (503.3M) | (541.5M) | (514.4M) | |
| Income Tax Expense | (30.1M) | 15.5M | (7.1M) | (29.5M) | (5.4M) | (5.6M) | |
| Total Revenue | 6.9M | 1.1B | 6.3M | 7.7M | 86.5M | 144.3M | |
| Gross Profit | 6.5M | 1.1B | 5.8M | 6.9M | 84.3M | 107.4M | |
| Net Income From Continuing Ops | (680.2M) | 606.1M | (457.9M) | (532.8M) | (655.9M) | (623.1M) | |
| Cost Of Revenue | 400K | 565K | 553K | 813K | 2.2M | 2.1M | |
| Non Operating Income Net Other | 82K | 250K | 134K | 15K | 17.3K | 16.4K | |
| Net Income Applicable To Common Shares | (680.2M) | 606.1M | (457.9M) | (532.8M) | (479.5M) | (455.5M) | |
| Net Interest Income | 27.8M | 9.6M | 2.9M | 14.2M | 36.1M | 37.9M | |
| Interest Income | 27.8M | 9.6M | 2.9M | 14.2M | 36.1M | 37.9M | |
| Reconciled Depreciation | 2.3M | 2.6M | 4.2M | 1.1M | 1.3M | 2.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share 1.76 | Quarterly Revenue Growth 3.371 | Return On Assets (0.30) | Return On Equity (0.49) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.